Pancreatic cancer (PC) is on the rise and is projected to become the second-leading cause of cancer-related deaths soon, with the worst prognosis among major cancers due to late diagnosis and resistance to treatment. The aggressive nature of PC creates high healthcare costs and demands intensive patient care.

Research shows that PC’s unique, immunosuppressive microenvironment, characterized by immature immune cells and suppressive cytokines, is a major barrier to effective treatment. Although current immunotherapies have limited impact, new research highlights a molecule called sialyl Tn (STn), an O-glycan that’s present in PC but absent in normal cells. STn contributes to cancer spread and immune suppression, creating an environment that allows PC to thrive and resist therapies.

Our studies suggest that STn may drive an immunosuppressive feedback loop, supported by cytokines like IL-6 and IL-13, which enhance STn expression and PC progression. Encouraging preliminary results show that high-affinity anti-STn antibodies demonstrate anti-tumor activity, making STn a promising target for future therapies. Further studies in patient cohorts are necessary to confirm these findings and potentially improve PC treatment outcomes by disrupting STn-driven immunosuppression.

An outstanding group of partners has been established to drive this project forward. Each member brings unique expertise and dedication, forming a collaborative team committed to achieving impactful results. Together, they contribute a wealth of knowledge and resources, ensuring the project’s success.